- Home
- CELH vs ROIV Comparison
CELH vs ROIV Comparison
Compare CELH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELH
- ROIV
- Stock Information
- Founded
- CELH 2004
- ROIV 2014
- Country
- CELH United States
- ROIV United Kingdom
- Employees
- CELH N/A
- ROIV N/A
- Industry
- CELH Beverages (Production/Distribution)
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CELH Consumer Staples
- ROIV Health Care
- Exchange
- CELH Nasdaq
- ROIV Nasdaq
- Market Cap
- CELH 15.7B
- ROIV 8.6B
- IPO Year
- CELH N/A
- ROIV N/A
- Fundamental
- Price
- CELH $65.40
- ROIV $17.95
- Analyst Decision
- CELH Strong Buy
- ROIV Strong Buy
- Analyst Count
- CELH 18
- ROIV 8
- Target Price
- CELH $62.61
- ROIV $19.94
- AVG Volume (30 Days)
- CELH 5.2M
- ROIV 7.4M
- Earning Date
- CELH 11-05-2025
- ROIV 11-11-2025
- Dividend Yield
- CELH N/A
- ROIV N/A
- EPS Growth
- CELH N/A
- ROIV N/A
- EPS
- CELH 0.39
- ROIV N/A
- Revenue
- CELH $1,666,480,000.00
- ROIV $23,233,000.00
- Revenue This Year
- CELH $84.05
- ROIV N/A
- Revenue Next Year
- CELH $29.58
- ROIV $200.91
- P/E Ratio
- CELH $164.33
- ROIV N/A
- Revenue Growth
- CELH 11.85
- ROIV N/A
- 52 Week Low
- CELH $21.10
- ROIV $8.73
- 52 Week High
- CELH $66.74
- ROIV $17.33
- Technical
- Relative Strength Index (RSI)
- CELH 69.85
- ROIV 85.74
- Support Level
- CELH $59.73
- ROIV $16.89
- Resistance Level
- CELH $66.74
- ROIV $16.39
- Average True Range (ATR)
- CELH 2.26
- ROIV 0.55
- MACD
- CELH 0.52
- ROIV 0.07
- Stochastic Oscillator
- CELH 87.57
- ROIV 95.93
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.